BJOG An International Journal of Obstetrics & Gynaecology · 1988 · 65 citations · 11 references
MedicineGynecologyPharmacotherapyReproductive EndocrinologyReproductive MedicineWomen's HealthHormonal EvaluationMenopause ManagementMenopause PharmacotherapyMenstrual CycleHormone Replacement RegimensIrregular Menstrual Bleeding ManagementIrregular Uterine BleedingVasomotor DysfunctionVasomotor Symptom ManagementVasomotor Symptoms
Sixty women with climacteric complaints who had not menstruated for at least 1 year were randomly allocated to receive one of four hormonal replacement regimens. All four formulations were administered daily and continuously and each contained 2 mg of micronized oestradiol-17 beta in combination with either norethisterone acetate 1 mg (group A) or 0.5 mg (group B) or megestrol acetate 5 mg (group C) or 2.5 mg (group D). The clinical efficacy was the same although the alleviation of vasomotor symptoms was somewhat slower in those women receiving preparation A. The endometrium was atrophied in nearly all biopsies. Irregular uterine bleeding was almost entirely confined to the earlier phase of the study and was substantially less with the formulation containing 1 mg norethisterone acetate. It is concluded that a continuous oestradiol-progestogen combination can be used for long-term treatment of climacteric complaints in postmenopausal women and that after 4 months the clinical efficacy is the same irrespective of the type and dose of progestogen administered.
11
Oral Medroxyprogesterone in the Treatment of Postmenopausal Symptoms
Isaac Schiff · JAMA · 1980 · 194 citations
Endometrial disease after treatment with oestrogens and progestogens in the climacteric.
M E Paterson, T. Wade‐Evans, David Sturdee et al. · BMJ · 1980 · 183 citations · Full text
Use of the progestogen challenge test to reduce the risk of endometrial cancer.
Gambrell Rd, Massey Fm, Castaneda Ta et al. · PubMed · 1980 · 170 citations
Medicine, Gynecology, Oncology +8